Associate Director, Asset Project Leadership

• Collaborate with functional leads across the BD and portfolio continuum to ensure seamless execution of data-driven in-licensing strategy.
• Leverage scientific acumen and diligence experience to refine and prioritize the most meaningful Recursion OS insights to ensure sourcing of unintuitive opportunities.
• Exploit bilingual proficiency across science/tech to overcome inefficiencies in search & evaluation and asset due diligence.
• Drive and enable a culture of accountability, ownership and scientific innovation aimed at delivering prioritized medicines to patient populations in need.

You will make significant contributions toward the advancement of transformative medicines for patients by leveraging advanced computational approaches and proprietary insights to industrialize and transform the development of medicines.

• PhD in life sciences or a related field.
• 5+ years of post-PhD experience in drug development within the biotech and/or pharmaceutical industry.
• Proven ability to assess innovative opportunities, conduct diligence on assets, and evaluate disparate licensing substrate across disease areas, MOAs and therapeutic approaches.
• Deep technical expertise in oncology, with strength in immunology/inflammation and metabolism a bonus.
• Demonstrable experience in translational, regulatory, biomarker and early ClinDev strategy.
• Incisive thinker with exceptional ability to decipher scientific complexity.
• Strong ability to prioritize and manage multiple tasks in a dynamic environment.
• Outstanding interpersonal and influencing skills.

Estimated annual base range of $180,600 to $229,000, plus eligibility for an annual bonus and equity compensation, and a comprehensive benefits package. This is an office-based, hybrid role requiring at least 50% in-office work in Salt Lake City or New York City.

Recursion is a clinical stage TechBio company leading the space by decoding biology to radically improve lives through its Recursion OS platform that generates one of the world's largest proprietary biological and chemical datasets and uses machine learning to advance the future of medicine.